SBIR Phase I: A new vaccine technology to engineer a potent and polarized immunity against COVID-19

这个小企业创新研究第一阶段项目的更广泛影响将推动一种新的疫苗交付技术，以对抗新出现的病原体，例如导致新冠肺炎的病原体。该项目将开发一种新的工艺，可以快速制造出具有高亲和力和精确工程免疫反应的工艺。这项技术是基于可以注入帮助支持免疫系统的新材料。这个小企业创新研究(SBIR)第一阶段项目将利用可流动的超多孔和合成材料推进一种新的疫苗交付技术。这种新的材料技术可以很容易地注射到皮下或肌肉内，以输送疫苗抗原。这种材料本身就是一种持久的抗原传递载体，增加抗体的产生，并使免疫系统两极分化，以最大限度地提高对所传递的抗原的保护性免疫力。该项目特别关注这种新型材料的开发，以创造对新型冠状病毒(SARS-CoV-2)的多因素免疫力，以防止COVID-19。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact of this Small Business Innovation Research (SBIR) Phase I project will advance a new vaccine delivery technology against new emerging pathogens such as that causing COVID-19. This project will develop a new process that can be rapidly manufactured with high affinity and precision-engineered immune responses. The technology is based on new materials that can be injected to help support the immune system.This Small Business Innovation Research (SBIR) Phase I project will advance a novel vaccine delivery technology using flowable hyper-porous and synthetic materials. This new material technology can be easily injected subcutaneously or intramuscularly to deliver vaccine antigens. The material itself acts as a long-lasting antigen delivery vehicle, increasing antibody production and polarizing the immune system to maximize protective immunity against the delivered antigens. This project specifically focuses on development of this novel material to create multifactor immunity against the novel coronavirus (SARS-CoV-2) to protect against COVID-19.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.